Patents by Inventor Gengmei Xing

Gengmei Xing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Metallofullerols and their applications for preparation of medicine for inhibition of tumor growth
    Patent number: 8124657
    Abstract: This invention provides a composition of polyhydroxylated metallofullerene compound and its application in the preparation of antitumor pharmaceutical. In one embodiment, metallofullerol comprising the formula, M@C2m(OH)x, wherein M is selected from rare earth elements such as La or Gd; m is carbon atoms of 41 or 30; x is a number of hydroxyl group of from 10 to about 50. Actually, due to the reset of the neighboring hydroxyl, the numbers of O and H in Carbon cage are different, formula are thus written as M@C2mOxHy. Comparing to the clinical anticancer drugs such as Paclitaxel, Cyclophosphamide, and Cisplatin, metallofullerol of M@C2m(OH)x or M@C2mOxHy has superior advantages of higher antitumor efficiency, low dosage, low toxicity, and better biocompatibility.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: February 28, 2012
    Assignee: Institute of High Energy Physics Chinese Academy of Sciences
    Inventors: Yuliang Zhao, Chunying Chen, Gengmei Xing
  • Metallofullerols and their Applications for Preparation of Medicine for Inhibition of Tumor Growth
    Publication number: 20090076171
    Abstract: This invention provides a composition of polyhydroxylated metallofullerene compound and its application in the preparation of antitumor pharmaceutical. In one embodiment, metallofullerol comprising the formula, M@C2m(OH)x, wherein M is selected from rare earth elements such as La or Gd; m is carbon atoms of 41 or 30; x is a number of hydroxyl group of from 10 to about 50. Actually, due to the reset of the neighboring hydroxyl, the numbers of O and H in Carbon cage are different, formula are thus written as M@C2mOxHy. Comparing to the clinical anticancer drugs such as Paclitaxel, Cyclophosphamide, and Cisplatin, metallofullerol of M@C2m(OH)x or M@C2mOxHy has superior advantages of higher antitumor efficiency, low dosage, low toxicity, and better biocompatibility.
    Type: Application
    Filed: September 15, 2006
    Publication date: March 19, 2009
    Inventors: Yuliang Zhao, Chunying Chen, Gengmei Xing